Agent Projects Move From Pilot to Production, Pushing Platform Teams to Set a Go-Live Bar
Diagrid publishes production-readiness criteria for AI agent deployments, showing what a demo proves and what teams need to support after launch FEDERAL WAY, Wash., Sept. 17, 2026 /PRNewswire/ -- Diagrid published a set of production-readiness...
Stalled Security Reviews Push Platform Teams to Define Who Owns AI Agent Authorization
Diagrid publishes a control-point checklist to help platform and security teams define ownership before an AI agent deployment reaches review FEDERAL WAY, Wash., Sept. 16, 2026 /PRNewswire/ -- Diagrid published a control-point checklist today for...
Results from Phase III Study of Trastuzumab Botidotin versus T-DM1 in HER2-Positive Breast Cancer Published in JCO
CHENGDU, China, Sept. 14, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or "the Company", 6990.HK) announced that results from the phase III registrational study of its novel human epidermal growth factor...
Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction
Interim MASTRR Registry analysis represents, to Aroa's knowledge, the largest published prospective bioscaffold analysis in in-patient soft tissue reconstruction AUCKLAND, New Zealand, Sept. 7, 2026 /PRNewswire/ -- Aroa Biosurgery Limited (ASX:...
As AI Visibility Budgets Reach Procurement, Buyers Are Finding Vendor Numbers Cannot Be Compared
Two proposals can report the same brand at 38% and 11% and both be arithmetically correct. XstraStar has published the denominator behind every metric it reports. SINGAPORE, August 12, 2026 /PRNewswire/ -- Spending on AI search visibility now passes...
Pope Leo XIV's writings verified by Proudly Human
MELBOURNE, Australia and ROME , July 21, 2026 /PRNewswire/ -- Proudly Human has today announced that Maps of Hope, a collection of speeches and writings by Pope Leo XIV on education and artificial intelligence, has been verified as human-authored,...
Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine
HANGZHOU, China, July 9, 2026 /PRNewswire/ -- On July 8, the study of Betta's ensartinib as postoperative adjuvant therapy for patients with stage IB–IIIB (T3N2M0) ALK-positive non-small cell lung cancer (NSCLC), known as the ELEVATE study, was...
Allianz Global Insurance Report 2026: The Future of Insurance in a Fragmenting World
World: Global premium pool expanded by +7.1% in 2025 – an increase of EUR456bn Singapore: Strong growth of +10.7% – due to double-digit growth in life and health insurance Outlook: Private protection remains a structurally growing need ensuring...
Roubini, Longtime Crypto Skeptic, Co-Authors Whitepaper and Backs Atlas's New Digital Reserve Asset
Atlas to launch USAFi, the first regulated permissionless security, under VARA's framework in Dubai Dr. Nouriel Roubini, long one of the most prominent critics of cryptocurrencies, makes his first move into digital assets, co-authoring the...
Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI. — The Company is conducting a Phase III registrational study of sac-TMT plus osimertinib as first-line...